DS Healthcare Group Moves Prescription Hair Loss Treatment Forward with Appointment of Aptiv Solutions as CRO
DS Healthcare Group, Inc announced it has appointed Aptiv Solutions as its CRO for its proprietary topical prescription treatment.
DS Healthcare Group, Inc. (NASDAQ:DSKX), a leading developer of personal care products, today announced it has appointed Aptiv Solutions as its clinical research organization (CRO) for its proprietary topical prescription treatment. If approved the drug will be positioned as frontline therapy in the fight against hair loss, a condition that affects nearly half of the population.
Aptiv Solutions will prepare DS Healthcare's Investigational New Drug Application(IND), for its proprietary topical hair loss treatment, for submission to the United Stated Food and Drug Administration (FDA). An IND is a request for the FDA's authorization to administer an investigational drug to humans and is the first step towards designing and conducting clinical trials in the U.S. To date, only one other topical treatment for hair loss has been approved by the FDA. Aptiv Solutions will also conduct a Gap analysis to ensure that DS Healthcare's operations are in line with regulatory requirements for drug approval.
Aptiv Solutions is a leading global CRO with extensive global drug development and trial management expertise. Aptiv Solutions has conducted over 2,600 clinical trials and assisted in over 140 FDA and European Union drug and biologic approvals, as well as over 700 medical device approvals and clearances. DS Healthcare recently announced its intention to submit an IND to the FDA. The move follows the Company's patent application filing with the United StatesPatent and Trademark Office for its prescription hair loss treatment invention.
"Our intention is to move the development of our prescription-grade hair loss product at a swift pace. Aptiv Solutions has been central to the successfuldevelopment, clinical trials, and subsequent regulatory approval of numerous market leading products and we are pleased to have their support as our CRO," commented DS Healthcare President and CEO, Daniel Khesin.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
